Nasometin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nasometin

What is Nasometin?

Nasometin is a medicinal product used for the treatment of inflammatory conditions affecting the nasal passages. It belongs to a group of medications known as corticosteroids, which are designed to reduce swelling and irritation in the lining of the nose.

Therapeutic Purpose

The medication is primarily used to manage symptoms associated with both seasonal and year-round allergic rhinitis. By acting locally on the nasal mucosa, it helps to alleviate physical discomforts such as congestion, sneezing, and itching.

Mechanism of Action

Nasometin works by inhibiting the release of substances in the body that cause inflammation. This localized action helps to decrease the sensitivity of the nasal tissues to environmental triggers. Unlike systemic medications, it focuses its effects directly on the area of application, which helps in maintaining a targeted therapeutic approach.

Applications in Nasal Health

In addition to treating allergy-related symptoms, Nasometin is also utilized for the management of nasal polyps. These are small, non-cancerous growths on the lining of the nasal passages or sinuses. The treatment aims to reduce the size of these polyps, thereby improving nasal airflow and reducing the sensation of pressure or blockage often experienced by patients with this condition.

What side effects are possible with Nasometin?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety considerations for Nasometin (mometasone furoate nasal spray) based on regulatory information.

Adverse Reactions by Frequency and System

Common Adverse Reactions (ge5% in clinical trials) include headache, viral infection, pharyngitis, epistaxis (nosebleeds), and cough.

System-Organ Classes involved include Respiratory, Thoracic, and Mediastinal Disorders (nasal effects); Infections and Infestations (viral, Candida); Nervous System Disorders (headache); and Immune System Disorders.

Serious and Clinically Significant Safety Concerns

Serious adverse reactions, though less common, are associated with the local and systemic effects of corticosteroids:

  • Local Nasal Effects: Nasal septal perforation, nasal ulceration that does not heal, and localized infection of the nose and pharynx with Candida albicans (thrush) have been reported.
  • Ocular Effects: Development or worsening of glaucoma (increased intraocular pressure) and cataracts may be reported, particularly with long-term use. Referral to an ophthalmologist may be considered for long-term users or those developing ocular symptoms.
  • Systemic Effects: Hypercorticism (Cushing’s Syndrome symptoms) and adrenal suppression (HPA axis effects) can occur, especially at higher-than-recommended dosages or in susceptible individuals.

Safety Restrictions and Monitoring

Contraindication: Nasometin is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients.

Cautionary Use: Use is restricted in patients with recent nasal surgery, nasal trauma, or unhealed nasal ulcers, due to the potential for impaired wound healing. Caution is also required in patients with active or quiescent tuberculosis, untreated fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex due to the risk of immunosuppression.

Pediatric Monitoring: Because nasal corticosteroids may cause a reduction in growth velocity in pediatric patients, routine monitoring of growth is recommended.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nasometin (Mometasone Furoate Nasal Spray) differentiates risks between acute and chronic excessive use. Due to the drug’s low systemic bioavailability, acute overdosage is unlikely to require any therapy other than observation, and accidental oral ingestion is expected to have little or no toxic effect. There is no specific antidote documented in official labeling.


Documented Manifestations and Outcomes

The primary regulatory concern is prolonged use at higher than recommended doses, which may result in systemic effects. These documented manifestations include signs of hypercorticism and Cushingoid features. Such excessive exposure may lead to clinically significant adrenal suppression and secondary adrenal insufficiency. Long-term complications documented in regulatory sources also include the risk of cataract and glaucoma. Population-specific notes identify growth retardation in children and adolescents as a potential systemic effect of prolonged high-dose exposure.


Mandated Emergency Action

Regulators mandate that a health care practitioner or Poison Control Centre be contacted immediately for any suspected overdose, even if there are no symptoms. Management for acute overdose is typically limited to observation. For evident chronic overdosage, the drug should be discontinued slowly, and additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

Therapeutic Uses of Nasometin

What Nasometin Treats: Main Uses and Benefits

Nasometin is applied across domains where additional symptomatic support is needed, especially in contexts marked by increased discomfort or tension. The medicine is commonly used for conditions presenting with acute episodes such as allergic rhinitis and nasal polyps. This focus is on managing symptoms that create noticeable physiological strain, such as sneezing, nasal itching, runny nose, and congestion.

The therapeutic approach helps to ease the overall symptom burden associated with these conditions. It provides supportive relief when symptoms interfere with routine activities and contributes to improved day-to-day comfort. The medicine is relevant in contexts involving recurrent or episodic manifestations where short-term symptom management is appropriate.


Quick Fact: Support for Nasal Congestion


Supporting Symptom Management for Seasonal and Year-Round Allergies

This therapeutic domain is relevant for easing symptoms that interfere with daily comfort. The medicine supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Supporting Symptomatic Relief for Nasal Polyps

The spray is commonly used across conditions characterized by periods of heightened symptoms, specifically for managing nasal polyps. It may assist with addressing the symptom clusters that may become intense or disruptive, helping to ease the overall symptom burden associated with these growths.

Eligibility and Restrictions for Use

Who can and cannot use Nasometin?

The eligibility for Nasometin (Mometasone Furoate Nasal Spray) is strictly defined by regulatory authorities based on specific patient populations and conditions.

Contraindicated Populations

The medicine is contraindicated for individuals with known hypersensitivity to mometasone furoate or any of its excipients. It must not be used by patients with recent nasal surgery, nasal trauma, or nasal septal ulcers until healing is complete, due to its inhibitory effect on wound repair. Use is also contraindicated in the presence of untreated localized infections, such as active tuberculosis or systemic fungal, bacterial, or viral infections.

Age-Specific Eligibility

Nasometin is approved for allergic rhinitis in patients 2 years of age and older. However, its use for the treatment of nasal polyps is not established in patients younger than 18 years old.

Conditional Use

In cases of pregnancy, use is generally not recommended unless the potential benefit to the mother outweighs the potential risk to the fetus. For breastfeeding mothers, a decision must be made to discontinue either the medication or breastfeeding. Use requires caution and monitoring in patients with pre-existing conditions like glaucoma or cataracts.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The potential for Nasometin (mometasone furoate) to interact with other medications is primarily related to its metabolism by specific liver enzymes and its classification as a corticosteroid.

Interacting Drug Categories and Mechanisms

The active ingredient, mometasone furoate, is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Therefore, coadministration with strong inhibitors of this enzyme can significantly increase the concentration of mometasone in the body. This increase in systemic exposure raises the risk of experiencing adverse effects associated with corticosteroids.

Interacting Category Mechanism/Restriction
Strong CYP3A4 Inhibitors Increase systemic exposure to mometasone, raising the risk of hypercorticism and HPA axis suppression.
Other Corticosteroids Risk of additive systemic effects (Hypercorticism, HPA axis suppression). Coadministration should be avoided.

Specific examples of strong CYP3A4 inhibitors explicitly cited in regulatory documents include ketoconazole, ritonavir, and cobicistat. The interaction with other corticosteroids—including oral tablets, injections, eye drops, or topical creams—is based on the cumulative effect of having multiple steroid products in the body at the same time.

Mechanism of Action

Nasometin, containing mometasone furoate, acts as a synthetic glucocorticoid receptor (GR) agonist. Following local tissue partitioning, the drug binds to cytosolic GRs, forming a ligand-receptor complex that translocates to the cell nucleus.

In the nucleus, the complex regulates gene expression through dual mechanisms: transrepression and transactivation.

Transrepression involves the inhibition of pro-inflammatory transcription factors, primarily nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1). This action suppresses the gene transcription of inflammatory mediators, including cytokines (e.g., IL-1beta, IL-6) and chemokines.

Transactivation involves binding to glucocorticoid response elements (GREs) to upregulate the transcription of anti-inflammatory proteins, notably annexin A1 (lipocortin-1). Annexin A1 inhibits phospholipase A2, thereby reducing the biosynthesis of eicosanoids (prostaglandins and leukotrienes).

This molecular and intracellular pathway convergence results in a systemic physiological modulation characterized by decreased vascular leakage, reduced localized inflammatory cell recruitment, and suppressed production of localized inflammatory signaling molecules.

Dosage and Administration Information

Administration Guidelines for Nasometin

Nasometin (mometasone furoate nasal spray) is for intranasal use only and is administered according to specific procedural steps and dosing rules.


Preparation and Administration Protocol

Prior to initial use, the pump must be primed by actuating ten times or until a fine spray is seen. If the nasal spray has not been used for more than one week, it must be reprimed by actuating two times or until a fine spray appears. This ensures the delivery of the correct dose. The product is administered as a metered spray into the nostril while breathing gently inward.


Dosing Schedule

The frequency of use is typically once daily or twice daily depending on the patient's age and condition, and should not exceed the maximum daily dose. The following dosage rules apply for the 50 mcg per spray concentration:

Age Group Dosing Schedule (Sprays/Nostril) Frequency Total Daily Dose (mcg)
Adults & Adolescents (12+ years) 2 sprays in each nostril Once daily 200
Children (2 to 11 years) 1 spray in each nostril Once daily 100
Adults (Nasal Polyps) 2 sprays in each nostril Twice daily 400

Use is restricted to patients 2 years of age and older. If a dose is missed, the user should take the missed dose as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. The next dose should be taken at the regular time, and the dose should not be doubled to compensate for the missed one.

Recent Clinical Evidence

Nasometin: Recent Clinical Evidence


Evidence for Symptom Relief in Allergic Rhinitis (Seasonal and Perennial)

The research base for Nasometin (Mometasone Furoate) in allergic rhinitis involves numerous controlled clinical trials, such as Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used in research exploring how symptoms change over time in populations where researchers examined symptoms related to both seasonal and year-round allergies.

Researchers measured patient-reported outcomes describing perceived discomfort using tools like the Total Nasal Symptom Score (TNSS). This composite score tracks outcomes linked to inflammatory or irritative states, such as sneezing, nasal itching, a runny nose, and nasal congestion. Studies reported measurements of symptom severity and observed patterns over the course of the trial periods. The evidence includes research focused on acute seasonal episodes and contributes to understanding symptom patterns in conditions characterized by fluctuating or episodic manifestations. Long-term data characterizing outcomes over periods exceeding 12 weeks are not fully established for perennial allergic rhinitis.


Evidence for Managing Nasal Polyps

Randomized Controlled Trials (RCTs) were the primary research method used to study outcomes related to nasal polyps in individuals. Researchers in the trials monitored physical measurement of polyp size/grade and patient-reported symptoms, particularly outcomes related to physical discomfort like nasal congestion and obstruction. Trials reported measurements of both the physical size of the polyps and the severity of associated symptoms.


What is Still Uncertain About Nasometin

The follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes or sustained patterns of observed changes. Additionally, research focused on comparing outcomes is limited for some of the supportive applications (such as acute rhinosinusitis), meaning that while research describes patterns of change, further studies are needed to fully characterize the research context.

Frequently Asked Questions (FAQ)

Common questions about Nasometin (FAQ)

Q: How quickly should I notice an effect after starting Nasometin?

Studies and official information indicate that some patients may notice a clinically significant onset of action within 12 hours after the first dose. However, the full therapeutic benefit may not be fully achieved within the first 48 hours. Consistent, regular use of the medicine is intended to help the drug achieve its full potential in symptom management.

Q: How is Nasometin different from a standard decongestant spray?

Nasometin is classified as an intranasal corticosteroid, which is intended to work by reducing inflammation and allergic response in the nasal lining. This differs from a standard decongestant spray, which works by acting as a vasoconstrictor to temporarily shrink blood vessels for immediate, short-term relief of congestion.

Q: Are there any special warnings for using Nasometin long-term?

Regulatory documents state that long-term use of nasal corticosteroids is generally associated with the need for periodic monitoring. This includes a potential risk related to the development or worsening of glaucoma or cataracts. Long-term use, especially at higher-than-recommended amounts, also carries a risk of systemic effects like Hypercorticism and adrenal suppression.

Q: Is a bitter taste in the throat a common effect of Nasometin?

Official reports indicate that side effects such as an unpleasant taste (dysgeusia) and unpleasant smell (dysosmia) have been reported by some users. While these are not listed among the most frequent adverse events in clinical trials, they have been reported as potential effects associated with the use of the nasal spray.

Q: Is it normal to experience dryness in the nose while using this spray?

Regulatory documents list a range of local nasal effects that have been reported by patients. While common effects include nosebleeds and throat irritation, other reported adverse reactions can include nasal burning and sometimes nasal dryness/irritation, which are reported adverse reactions.

Q: Is Nasometin safe to use with other allergy tablets?

Official information explicitly warns against using Nasometin alongside strong medications known as CYP3A4 inhibitors (such as certain anti-fungal or HIV medicines). This is because these combinations may potentially increase the drug’s concentration in the body. The product information does not generally list specific interactions with common, non-corticosteroid oral antihistamine tablets.

Q: How long can Nasometin be used before needing a doctor's review?

For the treatment of nasal polyps, official documents state that if symptoms are not adequately controlled after a specific time (such as 5 to 6 weeks) of treatment, regulatory documents indicate that alternative therapies may be explored. Furthermore, long-term use necessitates periodic monitoring for potential ocular and systemic effects.

Q: Can Nasometin be used in combination with other nasal sprays?

Regulatory documents caution against combining this product with other corticosteroids (whether they are oral, injectable, topical, or other nasal sprays). This is due to the risk of additive systemic effects, as noted in regulatory sources. No specific general restriction is cited regarding non-steroid nasal sprays, such as saline.

Q: Can Nasometin affect the sense of smell?

A change in the sense of smell (dysosmia) and taste has been reported as an adverse reaction in official regulatory summaries. The documentation notes that the exact frequency of this side effect is not known.

Q: Is Nasometin described as a preventive or a treatment medication?

Official documentation indicates the drug is used for both treatment and prevention. It is indicated for the treatment of existing symptoms of allergic rhinitis. However, for those with a known history of severe seasonal allergies, it may also be used as a prophylactic treatment (prevention) started up to four weeks before the expected allergy season begins.

Q: How does the spray function work to deliver the medicine?

Nasometin is provided as an aqueous suspension, meaning the active ingredient is suspended in a liquid base. The device features a pump designed to deliver a consistent, metered dose—a precise, measured amount of the suspension—with each single activation. This mechanism supports the uniform delivery of the medication onto the nasal lining.

Q: Can Nasometin be used for non-allergy nasal congestion?

The regulatory indications for Nasometin are specifically for allergic rhinitis (seasonal and perennial) and nasal polyps. Use for general congestion not related to these specific approved conditions is outside the scope of regulatory approval.

Q: Can I drink alcohol while using Nasometin?

Regulatory documents do not specifically list alcohol as a contraindication or interaction with this medicine. Since regulatory documents do not provide specific guidance on this matter, general medical practice involves reviewing the use of any medication with alcohol with a healthcare professional.

Q: Is Nasometin available over-the-counter or only by prescription?

In some countries, mometasone furoate nasal spray is available in two classifications. It may be available as a prescription-only medicine (POM) for certain uses, such as nasal polyps, or available over-the-counter (OTC) under the guidance of a pharmacist for temporary relief of allergic symptoms.

Q: What is the definition of the active ingredient in Nasometin?

The active ingredient, Mometasone Furoate, is chemically defined in official sources as a synthetic, 17-heterocyclic glucocorticoid. This substance belongs to the corticosteroid family and is recognized for its characteristic anti-inflammatory, antipruritic, and vasoconstrictive properties.

Q: Is Nasometin habit-forming or addictive?

The official product information does not contain specific warnings regarding the medicine being habit-forming, nor is it listed as a controlled substance by regulatory bodies. This status suggests that the product is not associated with recognized abuse potential.

Q: What if the spray bottle looks empty but still contains liquid?

Official patient instructions define the usable life of the product either by the number of metered sprays delivered or a specific time limit after first opening (e.g., 2 months), rather than the visible liquid level. The device is designed to ensure the correct dose is delivered up until the labeled number of sprays have been reached.

Q: Are there studies on Nasometin use in the elderly?

For the indicated uses, official dosing instructions generally group adults and older patients (geriatric) together, recommending the same initial dosage. This indicates that the dosage recommendations for the elderly population are consistent with those for other adult populations.

Q: Does Nasometin interact with grapefruit juice or other foods?

Grapefruit juice is listed in some regulatory summaries as a potential food interaction. This is because grapefruit juice may inhibit the CYP3A4 enzyme, which is involved in the metabolism of the active ingredient. Consistent consumption may potentially increase the systemic exposure to the drug.

Q: Is Nasometin used to treat chronic sinusitis?

Regulatory documents confirm the approval of mometasone furoate nasal spray for treating inflammation of the nose and sinuses associated with nasal polyps. It may also be used in the treatment of acute rhinosinusitis, but its regulatory use for general chronic sinusitis (lasting over 12 weeks) is often treated with different approaches or is not specifically covered by the product's primary indication.

Q: Why is Nasometin sometimes prescribed for a long period?

The drug is indicated for managing conditions that are frequently chronic or long-lasting. These include perennial allergic rhinitis (year-round allergies) and the management of nasal polyps. For effective long-term symptom control in these conditions, continuous, regular application is often necessary.

Q: Is it necessary to clean the Nasometin nozzle after every use?

Official patient instructions advise that the spray nozzle should be cleaned periodically, such as weekly, or according to the specific instructions provided with the product. The instructions indicate that cleaning after every single use is generally not required.

How should Nasometin be stored and disposed of?

How to Store and Dispose of Nasometin?

Strict adherence to official storage and disposal requirements is essential for maintaining product safety and stability.

Official Storage Requirements

Condition Requirement
Temperature Store between 2 C and 25 C (approximately 36 F to 77 F).
Protection Do not freeze. Protect from light. Keep the container tightly closed.
Stability Discard the bottle within 2 months after first opening, or once the labeled number of sprays is reached.

Handling and Disposal

Before use, the bottle must be shaken well and reprimed if unused for more than one week. The medicine must always be kept out of the sight and reach of children.

To dispose of unused or expired Nasometin, it must not be placed in household trash or poured down a sink or toilet. Consult a pharmacist or utilize a local medicine take-back program for official disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nasometin found in:

A-Z Index: